A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma.
A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma. Clin Genitourin Cancer. 2013 Jun; 11(2):100-6.